Condition: Platinum-resistant Ovarian Cancer · Refractory Ovarian Carcinoma · Sponsor: Cybrexa Therapeutics
The purpose of this study is to assess the safety, tolerability, and efficacy of CBX-12 in female subjects with platinum resistant or refractory ovarian cancer at 2 doses; 125 mg/m2 every 21 days or 100 mg/m2 every 21 days.
This description comes directly from the study's public registry record.
Clinical Operations Trial Team · 860-717-2731 · clinicalstudies@cybrexa.com
Always discuss trial participation with your own doctor first.
| Honor Health | Scottsdale, Arizona, United States | Withdrawn |
| Arizona Oncology Associates | Tucson, Arizona, United States | Active Not Recruiting |
| Usc Norris Comprehensive Cancer Center | Los Angeles, California, United States | Active Not Recruiting |
| Yale University School of Medicine | New Haven, Connecticut, United States | Active Not Recruiting |
| D&H Cancer Research Center | Margate, Florida, United States | Active Not Recruiting |
| South Florida Gynecology | Tampa, Florida, United States | Active Not Recruiting |
| Northwest Cancer Centers | Dyer, Indiana, United States | Withdrawn |
| Norton Cancer Institute | Louisville, Kentucky, United States | Active Not Recruiting |
| Women's Cancer Care | Covington, Louisiana, United States | Active Not Recruiting |
| Pci Nyu Langone Health | New York, New York, United States | Active Not Recruiting |
| Albert Einstein College of Medicine Montefiore Medical | New York, New York, United States | Active Not Recruiting |
| University Hospitals Seidman Cancer Center | Cleveland, Ohio, United States | Active Not Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06315491